Company: RCUS
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001724521-25-000052
Chunk: 55

Company: Arcus Biosciences, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 55
---
 |                 |   |     |         — |     |                 |   |
|                      |     | 1/23/2024 |     |           |     |             |  26,056 |     |                              -2 |         |     |               |  87,644 |     |        |     | 15.44 |     |          |       |     |   | 1/22/2034 |            |     |           |     |      — |     |                 |   |     |         — |     |                 |   |
|                      |     | 8/23/2022 |     |           |     |             |       — |     |                                 |         |     |               |       — |     |        |     |     — |     |          |       |     | — |           |            |     |           |     | 21,250 |     |              -6 |   |     |   316,413 |     |                 |   |
|                      |     | 1/23/2023 |     |           |     |             |       — |     |                                 |         |     |               |       — |     |        |     |     — |     |          |       |     | — |           |            |     |           |     | 17,000 |     |              -5 |   |     |   253,130 |     |                 |   |
|                      |     | 1/23/2024 |     |           |     |             |       — |     |                                 |         |     |               |       — |     |        |     |     — |     |          |       |     | — |           |            |     |           |     | 21,000 |     |              -5 |   |     |   312,690 |     |                 |   |

(1) For the purpose of determining market value, we assumed a stock price of $14.89, the closing sale price per share of our common stock on December 31, 2024, the last business day of our last fiscal year.

(2) The shares subject to this option vest in 48 substantially equal monthly installments commencing on January 1 of the year of grant provided the officer remains in our continuous service through each vesting date.

(3) The shares subject to this option are fully vested.

(4) The shares subject to this